These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33458618)

  • 1. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes.
    Lee S; Goyal A; Perelson AS; Ishida Y; Saito T; Gale M
    iScience; 2021 Jan; 24(1):101969. PubMed ID: 33458618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
    Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
    Viral Immunol; 2021 Oct; 34(8):531-541. PubMed ID: 34030480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
    Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
    J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
    Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
    J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
    Yang Y; Zhao X; Wang Z; Shu W; Li L; Li Y; Guo Z; Gao B; Xiong S
    Hepatology; 2020 Apr; 71(4):1154-1169. PubMed ID: 31402464
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tu T; Zehnder B; Qu B; Urban S
    JHEP Rep; 2021 Feb; 3(1):100195. PubMed ID: 33385130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein.
    Li Y; He M; Gong R; Wang Z; Lu L; Peng S; Duan Z; Feng Y; Liu Y; Gao B
    J Virol; 2022 Jul; 96(13):e0054622. PubMed ID: 35695580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I.
    Schnell G; Loo YM; Marcotrigiano J; Gale M
    PLoS Pathog; 2012; 8(8):e1002839. PubMed ID: 22912574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
    Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
    Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonproductive Hepatitis B Virus Covalently Closed Circular DNA Generates HBx-Related Transcripts from the HBx/Enhancer I Region and Acquires Reactivation by Superinfection in Single Cells.
    Peng B; Jing Z; Zhou Z; Sun Y; Guo G; Tan Z; Diao Y; Yao Q; Ping Y; Li X; Ren T; Li B; Li W
    J Virol; 2023 Jan; 97(1):e0171722. PubMed ID: 36475867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.
    Pattabhi S; Wilkins CR; Dong R; Knoll ML; Posakony J; Kaiser S; Mire CE; Wang ML; Ireton RC; Geisbert TW; Bedard KM; Iadonato SP; Loo YM; Gale M
    J Virol; 2015 Dec; 90(5):2372-87. PubMed ID: 26676770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
    Yang HC; Kao JH
    Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat Shock Protein Family A Member 1 Promotes Intracellular Amplification of Hepatitis B Virus Covalently Closed Circular DNA.
    Tang L; An P; Zhao Q; Winkler CA; Chang J; Guo JT
    J Virol; 2023 Jan; 97(1):e0126122. PubMed ID: 36519896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
    Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The U-Rich Untranslated Region of the Hepatitis E Virus Induces Differential Type I and Type III Interferon Responses in a Host Cell-Dependent Manner.
    Sooryanarain H; Heffron CL; Meng XJ
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a first-in-class orally available HBV cccDNA inhibitor.
    Wang L; Zhu Q; Zhang JD; Zhang Y; Ni X; Xiang K; Jiang J; Li B; Yu Y; Hu H; Zhang M; Wu W; Zeng J; Yan Z; Dai J; Sun K; Zhang X; Chen D; Feng S; Sach-Peltason L; Young JAT; Gao L
    J Hepatol; 2023 Apr; 78(4):742-753. PubMed ID: 36587899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.